Valeant Pharmaceuticals Intl Inc (NYSE:VRX)‘s stock had its “buy” rating restated by analysts at Mizuho in a research report issued on Wednesday, Marketbeat.com reports.
An institutional investor recently raised its position in Valeant Pharmaceuticals Intl stock. Meag Munich Ergo Kapitalanlagegesellschaft increased its stake in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) by 6.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 73,800 shares of the specialty pharmaceutical company’s stock after buying an additional 4,600 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft’s holdings in Valeant Pharmaceuticals Intl were worth $12,732,000 as of its most recent filing with the SEC.
Valeant Pharmaceuticals Intl (NYSE:VRX) traded up 8.10% during mid-day trading on Wednesday, reaching $118.47. 23,223,583 shares of the company’s stock were exchanged. The firm’s 50-day moving average is $90.53 and its 200 day moving average is $187.22. Valeant Pharmaceuticals Intl has a 1-year low of $69.33 and a 1-year high of $263.81. The stock has a market capitalization of $40.65 billion and a PE ratio of 68.05.
Valeant Pharmaceuticals Intl (NYSE:VRX) last released its quarterly earnings data on Monday, October 19th. The specialty pharmaceutical company reported $2.74 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.06. The company had revenue of $2.79 billion for the quarter, compared to analysts’ expectations of $2.06 billion. The firm’s quarterly revenue was up 35.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.58 EPS. Analysts forecast that Valeant Pharmaceuticals Intl will post $2.89 earnings per share for the current fiscal year.
In other news, Director Ronald Harold Farmer bought 1,500 shares of the firm’s stock in a transaction on Wednesday, October 21st. The stock was bought at an average cost of $181.60 per share, for a total transaction of $272,400.00. Following the completion of the acquisition, the director now directly owns 15,532 shares in the company, valued at approximately $2,820,611.20. The purchase was disclosed in a document filed with the SEC, which is available at this link.
VRX has been the topic of a number of other research reports. Vetrdowngraded shares of Valeant Pharmaceuticals Intl from a “strong-buy” rating to a “buy” rating and set a $122.10 price objective on the stock. in a report on Monday, October 26th. BMO Capital Markets decreased their price objective on shares of Valeant Pharmaceuticals Intl from $285.00 to $273.00 and set an “outperform” rating on the stock in a report on Friday, October 16th. Deutsche Bank reissued a “hold” rating and set a $204.00 price objective (down previously from $220.00) on shares of Valeant Pharmaceuticals Intl in a report on Tuesday, October 20th. Canaccord Genuity reissued a “buy” rating and set a $235.00 price objective on shares of Valeant Pharmaceuticals Intl in a report on Sunday, October 18th. Finally, Stifel Nicolaus decreased their price objective on shares of Valeant Pharmaceuticals Intl from $285.00 to $200.00 and set a “buy” rating on the stock in a report on Wednesday, November 11th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $163.62.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (NYSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.